Europäische Union - Dänisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - katte - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against chlamydophila felis infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus, chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the chlamydiosis and feline leukaemia components, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europäische Union - Dänisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain), attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katte - active immunisation of cats aged eight weeks and older:• against feline viral rhinotracheitis to reduce clinical signs;• against calicivirus infection to reduce clinical signs;• against chlamydophila felis infection to reduce clinical signs;• against feline panleucopenia to prevent mortality and clinical signs. immunitetstrin har vist sig en uge efter primærvaccinationskursus for rhinotracheitis, calicivirus, chlamydophila felis og panleucopenia komponenter. the duration of immunity is one year after the last re-vaccination for the chlamydiosis component, and oneyear after primary vaccination and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europäische Union - Dänisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated feline panleucopenia virus (pli iv), felv recombinant canarypox virus (vcp97) - immunologicals for felidae, - katte - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs ;against feline panleucopenia to prevent mortality and clinical signs;against leukaemia to prevent persistent viraemia and clinical signs of the related disease. onsets of immunity are 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component. the duration of immunity is one year after the last re-vaccination for the feline leukaemia component, and one year after primary vaccination course and three years after the last re-vaccination for the rhinotracheitis, calicivirosis and panleucopenia components.

Europäische Union - Dänisch - EMA (European Medicines Agency)

merial - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains), attenuated chlamydophila felis (905 strain) - immunologicals for felidae, - katte - active immunisation of cats aged 8 weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs and excretion;against chlamydophila felis infection to reduce clinical signs. immunitetsbegyndelser er blevet påvist 1 uge efter primærvaccinationskursus for rhinotracheitis, calicivirus og chlamydophila felis komponenter. varigheden af ​​immunitet er 1 år efter den sidste (re) vaccination.

Europäische Union - Dänisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline rhinotracheitis herpesvirus (fhv f2 strain), inactivated feline calicivirosis antigens (fcv 431 and g1 strains) - immunologicals for felidae, - katte - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs. onsets of immunity isone week after primary vaccination course. the duration of immunity is one year after primary vaccination course and three years after the last re-vaccination.

Europäische Union - Dänisch - EMA (European Medicines Agency)

virbac s.a. - purified p45 feline leukaemia virus envelope antigen, live feline calicivirus (strain f9), live feline viral rhinotracheitis virus (strain f2), live feline panleucopenia virus - levende felin panleucopenia virus / parvovirus + levende felin bovis virus + levende felin calicivirus + inaktiveret felin leukæmi virus - katte - til aktiv immunisering af katte fra otte uger mod: feline calicivirosis for at reducere kliniske tegn. feline viral rhinotracheitis for at reducere kliniske tegn og viral udskillelse. feline panleucopeni for at forhindre leukopeni og reducere kliniske tegn. feline leukæmi for at forhindre vedvarende viraemia og kliniske tegn på den relaterede sygdom. immunitetens begyndelse: 3 uger efter den primære vaccination for panleucopeni og leukæmikomponenterne og 4 uger efter den primære vaccination for calicivirus- og rhinotracheitisviruskomponenterne. immunitetens varighed: et år efter den primære vaccination for alle komponenter.

Europäische Union - Dänisch - EMA (European Medicines Agency)

boehringer ingelheim vetmedica gmbh - attenuated feline panleucopenia virus (pli iv) - immunologicals for felidae, - katte - active immunisation of cats aged eight weeks and older:against feline viral rhinotracheitis to reduce clinical signs;against calicivirus infection to reduce clinical signs;against feline panleucopenia to prevent mortality and clinical signs. onset of immunity is one week after primary vaccination course the duration of immunity is one year after the primary vaccination course and three years after the last re-vaccination.

Europäische Union - Dänisch - EMA (European Medicines Agency)

zoetis belgium sa - hundesyge-virus, stamme cdv bio 11/en, canine adenovirus type 2, stamme cav-2 bio 13, parvovirus type 2b, stamme cpv-2b bio 12/b og canine parainfluenza type 2-virus, stamme cpiv-2 mia 15 (alle levende, svækkede) - immunologicals for canidae, live viral vacciner - hunde - aktiv immunisering af hunde fra seks uger. for at forhindre, dødelighed og kliniske tegn forårsaget af hundesyge-virus,for at forhindre, dødelighed og kliniske tegn forårsaget af canine adenovirus type 1,for at forhindre kliniske tegn og reducere viral udskillelse forårsaget af canine adenovirus type 2,for at forhindre kliniske tegn, leukopeni og viral udskillelse forårsaget af parvovirus,for at forebygge kliniske symptomer, og reducere viral udskillelse forårsaget af canine parainfluenza virus.

Europäische Union - Dänisch - EMA (European Medicines Agency)

zoetis belgium sa - hundesyge-virus, stamme cdv bio 11/en, canine adenovirus type 2, stamme cav-2 bio 13, parvovirus type 2b, stamme cpv-2b bio 12/b, canine parainfluenza type 2-virus, stamme cpiv-2 mia 15 (alle levende, svækkede), leptospira interrogans serogruppe australis serovar bratislava, stamme mslb 1088, l. interrogans serogruppe icterohaemorrhagiae serovar icterohaemorrhagiae, stamme mslb 1089, l. interrogans serogruppe canicola serovar canicola, stamme mslb 1090, l. kirschneri serogruppe grippotyphosa serovar grippotyphosa, stamme mslb 1091... - live hundesyge-virus + live canine adenovirus + live canine parainfluenza virus + live parvovirus + inaktiveret leptospira, immunologicals for canidae - hunde - aktiv immunisering af hunde fra 6 ugers alderen:for at forhindre, dødelighed og kliniske tegn forårsaget af hundesyge-virus,for at forhindre, dødelighed og kliniske tegn forårsaget af canine adenovirus type 1,for at forhindre kliniske tegn og reducere viral udskillelse forårsaget af canine adenovirus type 2,for at forhindre kliniske tegn, leucopoenia og viral udskillelse forårsaget af parvovirus,for at forhindre, at kliniske tegn (nasal og øjenskader decharge) og reducere viral udskillelse forårsaget af canine parainfluenza virus,for at forhindre, at kliniske tegn, infektion og urinudskillelse forårsaget af l. interrogans serogruppe australis serovar bratislava,for at forhindre kliniske tegn og urinudskillelse og reducere infektion forårsaget af l. interrogans serogruppe canicola serovar canicola og l. interrogans serogruppe icterohaemorrhagiae serovar icterohaemorrhagiae og for at forhindre kliniske symptomer og reducere infektion og urin udskillelse forårsaget af l. interrogans serogruppe grippotyphosa serovar grippotyphosa.

Europäische Union - Dänisch - EMA (European Medicines Agency)

zoetis belgium sa - hundesyge-virus, stamme cdv bio 11/en, canine adenovirus type 2, stamme cav-2 bio 13, parvovirus type 2b, stamme cpv-2b bio 12/b, canine parainfluenza type 2-virus, stamme cpiv-2 mia 15 (alle levende, svækkede), leptospira interrogans serogruppe australis serovar bratislava, stamme mslb 1088, l. interrogans serogruppe icterohaemorrhagiae serovar icterohaemorrhagiae, stamme mslb 1089, l. interrogans serogruppe canicola serovar canicola, stamme mslb 1090, l. kirschneri serogruppe grippotyphosa serovar grippotyphosa, stamme mslb 1091... - live hundesyge-virus + live canine adenovirus + live parainfl.virus + live parvovirus + rabies, inaktiveret + inaktiveret leptospira, immunologicals for canidae - hunde - aktiv immunisering af hunde fra 8-9 uger gamle:for at forhindre, dødelighed og kliniske tegn forårsaget af hundesyge-virus,for at forhindre, dødelighed og kliniske tegn forårsaget af canine adenovirus type 1,for at forhindre kliniske tegn og reducere viral udskillelse forårsaget af canine adenovirus type 2,for at forhindre kliniske tegn, leucopoenia og viral udskillelse forårsaget af parvovirus,for at forhindre, at kliniske tegn (nasal og øjenskader decharge) og reducere viral udskillelse forårsaget af canine parainfluenza virus,for at forhindre, at kliniske tegn, infektion og urinudskillelse forårsaget af l. interrogans serogruppe australis serovar bratislava,for at forhindre kliniske tegn og urinudskillelse og reducere infektion forårsaget af l. interrogans serogruppe canicola serovar canicola og l. interrogans serogruppe icterohaemorrhagie serovar icterohaemorrhagiae,for at forebygge kliniske symptomer, og reducere infektion og urinudskillelse forårsaget af l. interrogans serogruppe grippotyphosa serovar grippotyphosa og for at forhindre dødelighed, kliniske tegn og infektion forårsaget af rabiesvirus.